Humacyte entered into an underwriting agreement to issue and sell 47,619,048 shares of common stock at a public offering price of $1.05 per share. The company granted underwriters a 30-day option to purchase an additional 7,142,857 shares. Expected net proceeds are approximately $46.80 million, potentially rising to $53.85 million if the underwriters' option is fully exercised. The offering is expected to close on or about June 12, 2026, subject to customary closing conditions.